Literature DB >> 16847283

Can trastuzumab be effective against tumors with low HER2/Neu (ErbB2) receptors?

Carlos L Arteaga.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16847283     DOI： 10.1200/JCO.2006.06.5268

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  9 in total

Review 1.  The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies.

Authors:  Anne W Hamburger
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-04-19       Impact factor: 2.673

2.  An update into the pathophysiological role of HER2 in cancer: therapeutic implications.

Authors:  A Ocaña; A Pandiella
Journal:  Clin Transl Oncol       Date:  2007-09       Impact factor: 3.405

3.  C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.

Authors:  Edith A Perez; Robert B Jenkins; Amylou C Dueck; Anne E Wiktor; Patrick P Bedroske; S Keith Anderson; Rhett P Ketterling; William R Sukov; Kazunori Kanehira; Beiyun Chen; Xochiquetzal J Geiger; Cathy A Andorfer; Ann E McCullough; Nancy E Davidson; Silvana Martino; George W Sledge; Peter A Kaufman; Leila A Kutteh; Julie R Gralow; Lyndsay N Harris; James N Ingle; Wilma L Lingle; Monica M Reinholz
Journal:  J Clin Oncol       Date:  2011-01-18       Impact factor: 44.544

4.  HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.

Authors:  Edith A Perez; Monica M Reinholz; David W Hillman; Kathleen S Tenner; Matthew J Schroeder; Nancy E Davidson; Silvana Martino; George W Sledge; Lyndsay N Harris; Julie R Gralow; Amylou C Dueck; Rhett P Ketterling; James N Ingle; Wilma L Lingle; Peter A Kaufman; Daniel W Visscher; Robert B Jenkins
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

5.  Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).

Authors:  Begoña Martin-Castillo; Cristina Oliveras-Ferraros; Alejandro Vazquez-Martin; Silvia Cufí; José Manuel Moreno; Bruna Corominas-Faja; Ander Urruticoechea; Ángel G Martín; Eugeni López-Bonet; Javier A Menendez
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

6.  Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831.

Authors:  Amylou C Dueck; Monica M Reinholz; Xochiquetzal J Geiger; Kathleen Tenner; Karla Ballman; Robert B Jenkins; Darren Riehle; Beiyun Chen; Ann E McCullough; Nancy E Davidson; Silvana Martino; George W Sledge; Peter A Kaufman; Leila A Kutteh; Julie Gralow; Lyndsay N Harris; James N Ingle; Wilma L Lingle; Edith A Perez
Journal:  Clin Cancer Res       Date:  2013-08-21       Impact factor: 12.531

Review 7.  Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer.

Authors:  Gabriella Mariani; Angelica Fasolo; Elena De Benedictis; Luca Gianni
Journal:  Nat Clin Pract Oncol       Date:  2008-12-23

8.  The level of HER2 expression is a predictor of antibody-HER2 trafficking behavior in cancer cells.

Authors:  Sripad Ram; Dongyoung Kim; Raimund J Ober; E Sally Ward
Journal:  MAbs       Date:  2014       Impact factor: 5.857

9.  Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited?

Authors:  Javier A Menendez; Ruth Lupu
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.